| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
This research project aimed to quantitatively evaluate relation and interaction among physiological pharmacokinetics of drugs, disease pharmacodynamics of host patients, and drug-resistance mechanisms of causative organisms, in order to optimize antimicrobial therapy. The research monitored concentrations of drugs, such as beta-lactams, quinolones, macrolides, imidazoles, anti-resistant-bacteria drugs, antifungals, and antivirals in plasma, peritoneal fluid, peritoneum, prostate and epididymis tissues. Being integrated with various minimum inhibitory concentration, pharmacodynamic time-killing and clinical data, these pharmacokinetic data were used for population modeling and simulation. Based on the relation and interaction among drug, host and organism, computer tools were created, applied to patients for optimizing antimicrobial therapy, and assessed with their feedback information.
|
